INVESTOR ALERT: Investigation of Inogen, Inc. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Inogen, Inc. (“Inogen” or the “Company”) (NASDAQ:INGN) concerning possible violations of federal securities laws. The investigation is focused on Inogen’s operations and internal controls over financial reporting.

Please contact Casey Sadler at 888-773-9224 or 310-201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

The investigation is related to certain statements issued by Inogen concerning the Company’s financial performance. On March 11, 2015, Inogen announced that certain “potential accounting matters” were discovered by management during first-quarter 2015, which prompted the Audit Committee, with the assistance of independent advisors, to commence an internal investigation. According to a Company press release, “the Audit Committee is investigating whether there were any violations of the Company’s accounting policies associated with these potential accounting matters.”

Following this news, Inogen shares dropped $4.24 per share, or more than 11% below the previous closing price, on March 12, 2015.

If you purchased Inogen securities, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.